1. Efficacy and safety of Micropulse® transscleral cyclophotocoagulation in glaucoma
- Author
-
N. Becerra, G. Iribarren, J. Sampaolesi, F. Lerner, F.G. Sanchez, Robert Noecker, and Tomas M. Grippo
- Subjects
medicine.medical_specialty ,genetic structures ,Adult patients ,business.industry ,Treatment duration ,Pseudoexfoliation ,Glaucoma ,Retrospective cohort study ,General Medicine ,medicine.disease ,03 medical and health sciences ,Heterogeneous population ,0302 clinical medicine ,Ophthalmology ,030221 ophthalmology & optometry ,medicine ,business ,Single session ,030217 neurology & neurosurgery - Abstract
Objective To report the results using Micropulse® transscleral cyclophotocoagulation (Iridex) in the treatment of glaucoma. Methods Retrospective study in adult patients with glaucoma with at least 6 months of follow-up, and only one session of Micropulse®. The same surgical technique was used in all cases. The only laser parameter that could vary was the total treatment duration (in seconds). The remaining parameters were fixed at 2 Watts of power and 0.5 ms (31.3%) of active cycle. Results A total of 22 eyes of 17 patients with glaucoma of various types and stages were included (mainly congenital and pseudoexfoliation). The mean follow-up time was 7.9 months. The total treatment duration varied from 100 to 180 s. Definition of success: 5 mmHg The overall success rate was 72.7% in the first month, 54% at 4 months, 41% at 6 months, and 27.3% at final follow-up. Patients with longer treatment durations (180 s) achieved better results. The mean reduction in IOP in successful eyes was 36% (from 26.3 to 16.7 mmHg, SD 4.58, p = 0.028). No complications were reported. Conclusions In a heterogeneous population of glaucoma (mostly congenital and pseudoexfoliation types), a low success rate (27.3%) was obtained in the medium-term with a single session of Micropulse®.
- Published
- 2018
- Full Text
- View/download PDF